These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 25512636)
21. The pathway ahead in melanoma trials. Miller AJ; Markovic SN; Haluska P Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690 [No Abstract] [Full Text] [Related]
22. Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. Falanga A; Marchetti M; Massi D; Merelli B; Verzeroli C; Russo L; Rulli E; Tondini C; Legramandi L; Nassini R; Scatena C; De Logu F; Cattaneo L; Mandalà M J Am Acad Dermatol; 2016 Jun; 74(6):1254-1256.e4. PubMed ID: 27185428 [No Abstract] [Full Text] [Related]
23. [BRAF mutation testing for the choice of melanoma treatment]. Imianitov EN Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664 [TBL] [Abstract][Full Text] [Related]
24. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma. Koop A; Satzger I; Alter M; Kapp A; Hauschild A; Gutzmer R Br J Dermatol; 2014 Jan; 170(1):220-2. PubMed ID: 24032672 [No Abstract] [Full Text] [Related]
25. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Seghers AC; Wilgenhof S; Lebbé C; Neyns B Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957 [TBL] [Abstract][Full Text] [Related]
26. BRAF in early stage melanoma: rationale for testing and treatment? Davies MA Br J Dermatol; 2015 Jul; 173(1):9-10. PubMed ID: 26174638 [No Abstract] [Full Text] [Related]
27. Standing on the shoulders of giants. Turajlic S Nat Med; 2019 Mar; 25(3):357. PubMed ID: 30842663 [No Abstract] [Full Text] [Related]
28. A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244). Boers-Sonderen MJ; Desar IM; Blokx W; Timmer-Bonte JN; van Herpen CM Anticancer Drugs; 2012 Aug; 23(7):761-4. PubMed ID: 22293660 [TBL] [Abstract][Full Text] [Related]
30. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Owen JL; Lopez IE; Desai SR J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671 [TBL] [Abstract][Full Text] [Related]
31. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Jang S; Atkins MB Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641 [TBL] [Abstract][Full Text] [Related]
33. Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer? Baroudjian B; Boussemart L; Routier E; Dreno B; Tao Y; Deutsch E; Blanchard P; Dhermain F; Vilcot L; Vagner S; Eggermont A; Mateus C; Robert C Eur J Dermatol; 2014; 24(2):265-7. PubMed ID: 24721778 [No Abstract] [Full Text] [Related]
34. Discovery and pharmacophore studies of novel pyrazole-based anti-melanoma agents. Li QS; Lü XH; Yang Y; Ruan BF; Yao RS; Liao CZ Chem Biodivers; 2015 Jan; 12(1):116-32. PubMed ID: 25641840 [TBL] [Abstract][Full Text] [Related]
35. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma. King JW; Nathan PD Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427 [TBL] [Abstract][Full Text] [Related]
36. Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Chen G; Davies MA Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945 [TBL] [Abstract][Full Text] [Related]